Cited by 101Extracellular vesicles in diseaseNanoparticle-Based Drug DeliveryMesenchymal stem cell research

Extracellular vesicles as personalized medicine

Open access
Beetler, Danielle J., Di Florio, Damian N., Bruno, Katelyn A., Ikezu, Tsuneya, March, Keith L., Cooper, Leslie T., Wolfram, Joy, Fairweather, DeLisa·2023·Molecular Aspects of Medicine

Abstract

Extracellular vesicles (EVs) are released from all cells in the body, forming an important intercellular communication network that contributes to health and disease. The contents of EVs are cell source-specific, inducing distinct signaling responses in recipient cells. The specificity of EVs and their accumulation in fluid spaces that are accessible for liquid biopsies make them highly attractive as potential biomarkers and therapies for disease. The duality of EVs as favorable (therapeutic) or unfavorable (pathological) messengers is context dependent and remains to be fully determined in homeostasis and various disease states. This review describes the use of EVs as biomarkers, drug delivery vehicles, and regenerative therapeutics, highlighting examples involving viral infections, cancer, and neurological diseases. There is growing interest to provide personalized therapy based on individual patient and disease characteristics. Increasing evidence suggests that EV biomarkers and therapeutic approaches are ideal for personalized medicine due to the diversity and multifunctionality of EVs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mam.2022.101155

Cites

261 of 261 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • It is possible that virus-containing EVs may be taken up by cells that do not express ACE2 using surface ligands on EVs.

    “Additionally, it is possible that virus-containing EVs may be taken up by cells that do not express ACE2 using surface ligands on EVs.”

    From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [51]

    Section 3.1 (page unavailable) reports that viral material, including SARS-CoV-2 RNA, can be found in EVs and that viruses can use EV receptors rather than their own receptors to enter host cells. It does not specifically establish uptake of virus-containing EVs by cells lacking ACE2 through EV surface ligands. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • Both the mRNA against the SARS-CoV-2 spike protein and the lipid nanoparticle vehicle could provide the adjuvant effect needed to promote myocarditis following vaccination with an mRNA vaccine.

    “Possibly both the mRNA against the SARS-CoV-2 spike protein and the lipid nanoparticle vehicle could provide the adjuvant effect needed to promote myocarditis following vaccination with an mRNA vaccine. 35,51,198”

    From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [51]

    Section 3.1 discusses extracellular vesicles, SARS-CoV-2 infection, and immune activation; section 4.3 discusses nanoparticles as drug-delivery vehicles. Neither addresses whether vaccine mRNA or its lipid nanoparticle vehicle could act as an adjuvant that promotes myocarditis. Searches for myocarditis, lipid nanoparticles, and mRNA-vaccine adjuvant effects found no passage making that connection; page numbers were unavailable in our copy. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

4 of the 265 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Feingold, K.R., 2000. Introduction to lipids and lipoproteins. In: Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Hershman, J.M., Hofland, J., Kalra, S., Kaltsas, G., Koch, C., Kopp, P., Korbonits, M., Kovacs, C.S., Kuohung, W., Laferrere, B., Levy, M., McGee, E.A., McLachlan, R., Morley, J.E., New, M., Purnell, J., Sahay, R., Singer, F., Sperling, M.A., Stratakis, C. A., Trence, D.L., Wilson, D.P. (Eds.), Endotext. South Dartmouth (MA).

Cited by

Sorted by citations

Authors
Beetler, D. J., Di Florio, D. N., Bruno, K. A., Ikezu, T., March, K. L., Cooper, L. T., Wolfram, J., & Fairweather, D.
Affiliations
  • Mayo Clinic (US)
  • University of Florida (US)
  • Mayo Clinic in Florida (US)
  • The University of Queensland (AU)
Corresponding author
Fairweather, DeLisa
Venue
Molecular Aspects of Medicine
Publisher
Elsevier BV
Published
2023-06
Volume
91
Pages
101155
ISSN
0098-2997 (ISSN-L)
OpenAlex
W4310099811
Cited by
101
References
265
Citations by year
2026: 23 · 2025: 30 · 2024: 28 · 2023: 20
FWCI
2.03
Type
journal article
Language
en
Open access
Locations
  • Molecular Aspects of Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
Funders
  • American Heart Association (R01 HL164520, 20TPA35490415, TL1 TR002380, R21 AI154927, R21 AI145356, R21 AI163302, R21 AI152318)
  • Ionis Pharmaceuticals
  • National Institutes of Health (20TPA35490415, UL1TR002556, AI154927, TR002380, TL1TR002380, UL1TR002377)
  • Advanced Research Projects Agency
  • National Institute on Aging (R01AG066429, RF1AG054199, R01AG054672, R01AG067763, R01AG072719, R01AG054199, R01AG076537)
  • National Heart, Lung, and Blood Institute (HL164520, R01HL164520)
  • National Institute of Allergy and Infectious Diseases (R21AI145356, 20TPA35490415, AI145356, R21AI163302, R21AI152318, R21AI154927)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
Keywords
extracellular vesicles, personalized medicine, liquid biopsy, biomarkers, drug carriers, intercellular communication, viral infection, cancer, neurological disorders
MeSH terms
Extracellular Vesicles, Liquid Biopsy, Humans, Biomarkers, Drug Delivery Systems, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review